Observational studyCurrent oncology (Toronto, Ont.)2026
Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
Samad Sayed et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.